For instance, FGFR3 expression is increased in tamoxifen-resistant breast tumours and FGFR3 activation in MCF7 cells activates the MAPK, PI3K and PLCγ pathways [220], confirming its putative role in breast cancer development and resistance to endocrine therapy. Here, FGFR3 is linked to breast carcinoma.